CS
AZN icon

Cannell & Spears’s AstraZeneca AZN Stock Holding History

Cannell & Spears’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$329K Sell
1,666
-1
-0.1% -$193 0.01% 348
2025
Q4 		$306K Hold
1,667
– – 0.01% 341
2025
Q3 		$256K Buy
1,667
+176
+12% +$26.6K ﹤0.01% 361
2025
Q2 		$208K Buy
1,491
+11
+0.7% +$1.54K ﹤0.01% 367
2025
Q1 		$218K Buy
+1,480
New +$214K ﹤0.01% 357
2024
Q4 		– Sell
-2,063
Closed -$321K – 397
2024
Q3 		$321K Buy
2,063
+408
+25% +$65.9K 0.01% 334
2024
Q2 		$258K Hold
1,655
– – 0.01% 319
2024
Q1 		$224K Hold
1,655
– – ﹤0.01% 351
2023
Q4 		$223K Hold
1,655
– – 0.02% 198
2023
Q3 		$224K Hold
1,655
– – 0.02% 188
2023
Q2 		$237K Hold
1,655
– – 0.02% 200
2023
Q1 		$230K Hold
1,655
– – 0.02% 204
2022
Q4 		$224K Buy
+1,655
New +$208K 0.02% 203
2022
Q3 		– Sell
-1,655
Closed -$219K – 194
2022
Q2 		$219K Hold
1,655
– – 0.02% 189
2022
Q1 		$220K Buy
+1,655
New +$198K 0.02% 211
2015
Q3 		– Sell
-3,656
Closed -$233K – 133
2015
Q2 		$233K Buy
3,656
+28
+0.8% +$1.92K 0.03% 129
2015
Q1 		$248K Buy
+3,628
New +$252K 0.03% 121

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Cannell & Spears's AZN Position: Q1 2026 in Review

Cannell & Spears reduced its AstraZeneca (AZN) stake by 0.06% in Q1 2026, selling an estimated $193 and leaving 1,666 shares worth $329K. The position accounts for 0.01% of the portfolio, ranked #348.

Cannell & Spears first reported a position in AZN in Q1 2015 and has held it in 17 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Cannell & Spears held 1,666 shares of AstraZeneca worth $329K as of Q1 2026.
  • Cannell & Spears sold 1 AstraZeneca share in Q1 2026, an estimated $193.
  • AstraZeneca made up 0.01% of Cannell & Spears's portfolio in Q1 2026, its #348 holding.
  • Cannell & Spears first reported a position in AstraZeneca in Q1 2015 and has held it in 17 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Cannell & Spears's 13F filing for Q1 2026, filed 14 May 2026.